Korro Bio, Inc. Operating Cash Flow
Korro Bio, Inc. (KRRO) reported Operating Cash Flow of -$33.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Korro Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$16.99M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$16.07M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.70M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.18M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$78.56M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$60.07M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$67.28M.
- Korro Bio, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$53.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$16.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$33.07M 10-Q · filed 2026-08-06 | -$50.77M derived: sum of 3 quarters · filed 2026-08-06 | -$67.95M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$16.07M 10-Q · filed 2026-05-07 | -$33.78M derived: sum of 2 quarters · filed 2026-05-07 | -$50.95M derived: sum of 3 quarters · filed 2026-05-07 | -$70.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$17.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$34.88M derived: sum of 2 quarters · filed 2026-03-12 | -$54.11M derived: sum of 3 quarters · filed 2026-08-06 | -$78.56M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$17.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$36.41M derived: sum of 2 quarters · filed 2026-08-06 | -$60.86M 10-Q · filed 2025-11-12 | -$68.35M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$19.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$43.68M 10-Q · filed 2026-08-06 | -$51.17M derived: sum of 3 quarters · filed 2026-08-06 | -$67.27M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$24.45M 10-Q · filed 2026-05-07 | -$31.95M derived: sum of 2 quarters · filed 2026-05-07 | -$48.04M derived: sum of 3 quarters · filed 2026-05-07 | -$62.63M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$23.59M derived: sum of 2 quarters · filed 2026-03-12 | -$38.18M derived: sum of 3 quarters · filed 2026-03-12 | -$60.07M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$16.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$30.69M derived: sum of 2 quarters · filed 2025-11-12 | -$52.58M 10-Q · filed 2025-11-12 | -$73.69M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$14.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$36.48M 10-Q · filed 2025-08-12 | -$57.59M derived: sum of 3 quarters · filed 2025-08-12 | -$69.36M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$21.89M 10-Q · filed 2025-05-07 | -$43.00M derived: sum of 2 quarters · filed 2025-05-07 | -$54.77M derived: sum of 3 quarters · filed 2025-05-07 | -$69.48M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | -$21.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$32.88M derived: sum of 2 quarters · filed 2025-03-18 | -$47.59M derived: sum of 3 quarters · filed 2025-03-18 | -$67.28M 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | -$11.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$26.49M derived: sum of 2 quarters · filed 2024-11-12 | -$46.18M 10-Q · filed 2024-11-12 | -$27.36M 10-Q · filed 2023-11-02 | -$57.20M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$14.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$34.40M 10-Q · filed 2024-08-13 | -$22.56M 10-Q · filed 2023-08-10 | -$45.43M derived: sum of 3 quarters · filed 2024-08-13 | -$57.23M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | -$19.69M 10-Q · filed 2024-05-14 | -$14.13M 10-Q · filed 2023-05-12 | -$30.72M derived: sum of 2 quarters · filed 2024-05-14 | -$42.51M derived: sum of 3 quarters · filed 2024-05-14 | -$55.99M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$22.82M derived: sum of 2 quarters · filed 2024-03-26 | -$36.30M derived: sum of 3 quarters · filed 2024-03-26 | -$53.65M 10-K · filed 2024-03-26 | -$58.24M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | -$11.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$25.27M derived: sum of 2 quarters · filed 2023-11-02 | -$42.62M 10-Q · filed 2023-11-02 | -$60.51M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | -$13.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$30.82M 10-Q · filed 2023-08-10 | -$48.71M derived: sum of 3 quarters · filed 2023-08-10 | -$63.73M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$17.34M 10-Q · filed 2023-05-12 | -$35.23M derived: sum of 2 quarters · filed 2023-05-12 | -$50.25M derived: sum of 3 quarters · filed 2023-05-12 | -$67.93M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | -$17.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$32.91M derived: sum of 2 quarters · filed 2023-03-10 | -$50.59M derived: sum of 3 quarters · filed 2023-03-10 | -$76.06M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | -$15.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$32.70M derived: sum of 2 quarters · filed 2022-11-08 | -$58.17M 10-Q · filed 2022-11-08 | -$73.00M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$17.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$43.15M 10-Q · filed 2022-08-09 | -$57.98M derived: sum of 3 quarters · filed 2022-08-09 | -$68.71M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$25.47M 10-Q · filed 2022-05-04 | -$40.31M derived: sum of 2 quarters · filed 2022-05-04 | -$51.04M derived: sum of 3 quarters · filed 2022-05-04 | -$61.30M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | -$14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$25.56M derived: sum of 2 quarters · filed 2022-03-15 | -$35.83M derived: sum of 3 quarters · filed 2022-03-15 | -$45.19M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$10.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$20.99M derived: sum of 2 quarters · filed 2021-11-15 | -$30.36M 10-Q · filed 2021-11-15 | -$60.10M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | -$10.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$19.63M 10-Q · filed 2021-08-12 | -$49.37M derived: sum of 3 quarters · filed 2021-08-12 | $25.21M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | -$9.36M 10-Q · filed 2021-05-13 | -$39.10M derived: sum of 2 quarters · filed 2021-05-13 | $35.48M derived: sum of 3 quarters · filed 2021-05-13 | $31.00M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | -$29.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $44.84M derived: sum of 2 quarters · filed 2021-03-29 | $40.37M derived: sum of 3 quarters · filed 2021-03-29 | $34.22M 10-K · filed 2021-03-29 | $34.22M 10-K · filed 2020-03-26 | |||
| 2019-09-30 | $74.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $70.11M derived: sum of 2 quarters · filed 2020-11-16 | $63.96M 10-Q · filed 2020-11-16 | $59.24M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | -$4.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$10.62M 10-Q · filed 2020-08-12 | -$15.34M derived: sum of 3 quarters · filed 2020-08-12 | |||||
| 2019-03-31 | -$6.15M 10-Q · filed 2020-05-14 | -$10.87M derived: sum of 2 quarters · filed 2020-05-14 | ||||||
| 2018-12-31 | -$4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$17.02M 10-K · filed 2020-03-26 | ||||||
| 2018-09-30 | -$12.30M 10-Q · filed 2019-11-18 | |||||||
| 2017-12-31 | -$14.61M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |